JP Morgan maintains Amgen at Neutral, raises price target to $425 from $350

What happened

JP Morgan maintained its Neutral rating on Amgen and raised its price target to $425 from $350, a 21.4% increase. The new target implies 7.9% downside from Amgen’s November 3 closing price of $461.26.

Confirmed

Global impact / market context

The higher target signals JP Morgan sees more value in Amgen than before, but its Neutral rating remains unchanged and the target is still below the cited closing price. If investors adjust their buying or selling in response, that trading could move Amgen shares, although the article reports no market reaction.

Analyst inference

Five recent analyst notes cited for Amgen have targets ranging from $398 to $536, with recommendations spanning Buy, Outperform, Equal-Weight, and Hold. JP Morgan’s $425 target falls within that spread, indicating differing analyst views rather than a clear consensus about the shares.

Confirmed

What to watch

1. Compare future analyst targets and ratings with JP Morgan’s $425 target and the cited $398–$536 range; converging views could shape investor positioning and share demand. Analyst inference
2. Watch for any change in JP Morgan’s rating or target. A different view could prompt investors to reassess expected share value and alter buying or selling decisions. Analyst inference
3. Track Amgen’s share price against the $425 target and the cited November 3 close of $461.26; the article gives no later price movement or explanation of operating results. Confirmed

Evidence

• Original source link unavailable